





































































































































	Because	of	its	worldwide	impact	on	human	health,	hepatitis	C	virus	(HCV)	is	among	the	most	 intensively	studied	human	pathogens.	Humans	are	 the	only	natural	host	 for	HCV	and	chimpanzees	the	only	animal	model.	Therefore,	HCV	research	is	mostly	restricted	to	in	vitro	 systems.	 In	particular,	 a	 robust	 in	vitro	HCV	 infection	 system	has	enabled	 the	accumulation	of	an	impressive	body	of	knowledge	on	basic	HCV	biology	and	viral-host	interactions	 in	 vitro.	 Not	 unexpectedly	 however,	 little	 research	 on	 the	 host-virus	interaction	and	the	 impact	of	antiviral	 therapy	in	the	human	liver	has	been	performed	mostly	due	to	the	challenges	and	difficulties	associated	with	collection	and	sampling	of	appropriate	human	liver	tissue.			In	the	first	part	of	our	work	we	investigated	the	impact	of	HCV	infection	on	the	cellular	homeostasis	of	hepatocytes	in	vivo.	The	challenge	for	such	an	analysis	lies	in	separating	direct	 responses	 to	 viral	 infection	 in	 the	 infected	 hepatocytes	 from	 the	 innate	 and	adaptive	immune	responses	associated	with	HCV	infection.	Furthermore,	the	strength	of	the	 immune	response	varies	considerable	 from	patient	 to	patient	 further	complicating	separation	 of	 direct	 and	 indirect	 responses	 to	 HCV	 infection.	 We	 therefore	 carefully	selected	 a	 set	 of	 biopsies	 without	 detectable	 immune	 response	 and	 compared	 high-throughput	transcriptome	sequencing	profiles	of	these	biopsies	with	biopsies	from	non-infected	patients.	These	studies	revealed	that	gene	expression	changes	mainly	reflect	the	presence	 of	 immune	 cell	 infiltrates	 in	 the	 HCV	 group	 without	 detectable	 immune	response.	 However,	 HCV	 infection	 does	 not	 trigger	 any	 significant	 gene	 expression	changes	 in	 the	 infected	 cells	 suggesting	 that	 many	 of	 the	 HCV	 induced	 changes	previously	 observed	 in	 vitro	 do	 not	 occur	 in	 the	 HCV-infected	 liver.	 This	 discrepancy	most	 likely	 is	 a	 reflection	 of	 the	 much	 higher	 viral	 RNA	 content	 per	 cell	 typically	observed	 in	 in	vitro	systems	compared	to	 the	viral	 load	 in	 the	hepatocytes	 in	 the	HCV	infected	liver.		In	the	second	part	we	investigated	a	long-standing	conundrum	in	the	field	regarding	the	inability	of	the	endogenous	IFN	system	activation	to	eradicate	HCV	infections.	Interferon	alpha	(IFNα)	has	been	the	backbone	of	anti-HCV	therapy	for	the	last	25	years.	Till	today	it	 is	unclear,	why	recombinant	IFNα	injected	during	therapies	 is	a	potent	antiviral	and	eradicates	HCV	in	about	50%	of	patients,	whereas	the	activation	of	the	endogenous	IFN	
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system	in	the	liver	is	ineffective.	We	performed	an	in-depth	transcriptome	analysis	of	a	unique	set	of	paired	liver	biopsies,	obtained	before	and	at	different	time	points	during	the	 first	 week	 of	 antiviral	 therapy	 using	 pegylated	 interferon	 alpha	 (pegIFNα).	 Our	analysis	provides	strong	evidence	that	quantitative	rather	than	qualitative	differences	in	gene	induction	are	responsible	for	the	failure	of	the	endogenous	IFNs	and	the	success	of	pegIFNα	in	viral	eradication	Finally	the	role	of	miR-122	and	other	non-coding	RNAs	in	response	to	HCV	infection	and	to	IFNα	therapy	in	the	liver	was	investigated.	In	vitro	studies	have	shown	that	binding	of	miR-122	by	HCV	can	regulate	host	gene	expression	by	reducing	(sponging)	the	amount	of	 miR-122	 available	 for	 gene	 repression1.	 We	 find	 that	 miR-122	 targets	 are	 not	significantly	up-regulated	in	response	to	HCV	infection	in	the	human	liver.	However,	we	show	 that	 the	precursor	 transcript	 of	miR-122,	 as	well	 as	 other	 long	non-coding	RNA	transcripts	that	act	as	precursors	for	miRNAs,	are	down-regulated	in	the	 infected	liver	during	peg	IFNα/ribavirin	treatment.	These	results	suggest	that	the	down-regulation	of	miRNAs	could	contribute	to	peg	IFNα/ribavirin-mediated	clearance	of	HCV	infection.				 	
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1. Introduction	
	1.1. Hepatitis	C	Infection		1.1.1. Epidemiology	and	natural	history		HCV	infections	are	a	major	cause	of	liver-related	morbidity	and	mortality.	An	estimated	160	million	persons	are	chronically	HCV	infected	worldwide	and	are	at	increased	risk	of	developing	 liver	 fibrosis,	 cirrhosis	 and	 hepatocellular	 carcinoma2.	 HCV	 was	characterized	in	1989	using	a	novel	experimental	approach	in	which	a	cDNA	expression	library	 that	 had	 been	 constructed	 from	 the	 plasma	 of	 a	 patient	with	 post-transfusion	non-A,	non-B	hepatitis	was	screened	 for	 the	unidentified	agent3.	Populations	at	risk	of	acute	 hepatitis	 C	 were	 patients	 who	 received	 blood	 products	 prior	 to	 1990,	 before	routine	 screening	 of	 blood	 products	 for	 HCV.	 Thus,	 in	 Europe	 and	 the	 USA,	 sero-prevalence	 increases	 with	 age	 and	 peaks	 in	 55–64	 year	 old	 patients4.	 Since	 the	introduction	of	routine	screening	of	blood	products	and	sterile	injection	needles	in	the	1990s,	 the	 principal	 cohorts	 of	 newly	 infected	 patients	 has	 changed.	 The	majority	 of	patients	 presenting	 as	 new	 cases	 in	 developed	 countries	 now	 are	 people	 who	 inject	drugs	 and	 men	 who	 have	 sex	 with	 men5.	 Despite	 considerable	 research	 efforts,	 a	prophylactic	vaccine	is	still	not	available.		The	acute	phase	is	often	clinically	mild	and	therefore	rarely	diagnosed.	(Figure	1).	The	initial	 features	 are	 non-specific	 flu-like	 symptoms,	 while	 more	 specific	 viral	 hepatitis	symptoms	 such	 as	 jaundice,	 dark	 urine	 and	 abdominal	 discomfort	 only	 occur	 in	 a	minority	 of	 individuals.	 Accurate	 studies	 of	 the	 time	 course	 for	 clearance	 of	 acute	hepatitis	 C	 infection	 are	 difficult	 to	 carry	 out	 because	 of	 the	 silent	 onset	 of	 the	 acute	disease.	In	the	available	studies,	the	rate	of	spontaneous	resolution	of	HCV	infections	is	reported	to	be	between	15–40%6,	7,	8.		Chronic	HCV	infection	is	defined	as	persistence	of	HCV	RNA	in	the	blood	for	more	than	six	months.	 Chronic	hepatitis	 is	 the	most	 common	outcome	of	HCV	 infection	 and	may	lead	 to	 fibrosis	 and	 cirrhosis	 of	 the	 liver.	 It	 is	 generally	 a	 slowly	 progressive	 disease	characterized	 by	 persistent	 hepatic	 inflammation	 leading	 to	 the	 development	 of	cirrhosis	 in	 approximately	 15–25%	 of	 patients	 over	 20–30	 years	 of	 HCV	 infection.	(Published	data	are	highly	variable	with	progression	 rates	 to	 cirrhosis	between	2–3%	
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Several	host	 cell	 factors	are	 required	 for	virus	 translation,	 replication	and	production.	These	 include	 liver-specific	 microRNA-122	 (miR-122),	 which	 was	 shown	 to	 interact	with	the	5'-NCR	of	the	HCV	genome	and	increase	HCV	abundance	in		replicon		models	29.	miR-122	 	was	 	 also	 	 implicated	 	 in	 HCV	 	 translation,	 	 reportedly	 	 by	 	 enhancing	 	 the		association	 	 of	 	 ribosomes	 	 with	 	 the	 viral	 RNA30.	 miR-122	 associates	 with	 host	Argonaute	2	to	bind	the	HCV	RNA,	and	through	this	interaction	stabilizes	the	viral	RNA31	and	most	 likely	protects	 its	 5’-NCR	 from	degradation32.	 It	was	 reported,	 that	HCV	has	also	sponge	effect	in	depleting	the	host	cell	for	miR-122	resulting	in	global	derepression	of	host	miR-122	targets1.		1.1.3. Model	systems	in	Hepatitis	C		Because	 of	 their	 substantial	 impact	 on	 human	 health,	 HCV	 infections	 have	 been	extensively	 studied	 and	 became	widely	 used	model	 systems	 to	 investigate	 host-virus	interactions33.	
In	vitro	models	Since	the	discovery	of	HCV	in	19893,	the	lack	of	a	suitable	cell	culture	and	small	animal	model	 systems	 represented	 a	major	 obstacle	 in	 studying	 the	 biology	 of	 the	 virus	 and	developing	 prophylactic	 and	 therapeutic	 interventions.	 Patient-derived	 HCV	 isolates	failed	to	initiate	productive	infection	in	cell	culture.	In	1997	HCV	molecular	clones	that	were	 infectious	 in	chimpanzees	were	developed,	however	 these	viral	genomes	did	not	produce	 viral	 particles	 in	 cell	 culture34,	 35.	 In	 1999,	 the	 group	 of	 Bartenschlager	developed	 an	 efficient	 cell	 culture	 replication	 model	 of	 HCV.	 These	 HCV	 replicons	contained	adaptive	mutations	 that	prevented	productive	 replication	 in	 chimpanzees36.	Moreover,	 the	 system	 did	 not	 support	 the	 full	 viral	 life	 cycle	 and	 did	 not	 produce	infectious	 viruses.	 The	 breakthrough	 came	 with	 the	 serendipitous	 discovery	 that	 an	isolate	from	a	Japanese	patient	with	fulminant	hepatitis	could	replicate	in	Huh7	derived	cell	lines	without	the	requirement	for	cell	culture	adaptive	mutations	and	produced	fully	infectious	 viral	 particles	 that	 were	 infectious	 in	 chimpanzees37,	 38,	 39.	 Following	 this	initial	 observations,	 a	 number	 of	 improved	 derivates	 of	 the	 original	 genotype	 2a	HCV	clone	have	been	generated	 and	 successfully	 tested	 in	 additional	 cell	 culture	model.	Of	note,	primary	human	hepatocytes	can	also	be	infected,	albeit	with	much	lower	efficiency	of	 infection	 and	 replication,	 and	 are	 considered	 to	 represent	 a	 more	 physiological	experimental	 system40,	41,	42.	However,	 poor	 availability	 of	 these	 cells,	 high	 costs,	 short	survival	 (up	 to	2	weeks)	 and	 the	 relative	poor	permissiveness	 for	HCV	 infection	have	
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limited	 HCV	 studies	 in	 PHH.	 Recently,	 hepatocyte-like	 cells	 derived	 from	 induced	pluripotent	stem	cells	(iPSC)	and	human	embryonic	stem	cells	(hESC)	have	been	shown	to	 be	 susceptible	 to	 HCV	 infection	 and	 could	 potentially	 offer	 improved	 in	 vitro	 HCV	infection	systems	in	the	future43,	44.		
































HCV	RNA	after	4	weeks	of	treatment	and	have	more	than	a	90%	chance	of	generating	an	SVR.		Combination	of	IFN	and	Ribavirin	(RBV)	Ribavirin	 is	 a	 nucleoside	 analogue	with	 a	 known	broad	 range	 of	 antiviral	 activities.	 It	had	already	been	tested	as	a	monotherapy	for	CHC	in	the	early	1990s	and	was	found	to	transiently	reduce	ALT	levels	during	treatment.	In	1998	the	first	randomized	controlled	trial	that	included	912	patients	showed	that	the	combination	of	subcutaneously	injected	IFNα2b	 with	 daily	 oral	 administration	 of	 RBV	 achieved	 an	 SVR	 in	 38%	 of	 treated	patients,	 which	 was	 an	 increase	 of	 more	 than	 20%	 compared	 with	 IFNα2b	monotherapy60.	After	 this	 study	 the	 combination	of	 IFNα2b	and	RBV	became	 the	new	standard	of	care.	However,	it	still	remains	unclear	how	RBV	boosts	the	response	to	IFNα.		
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Pegylated	IFNα	Pegylation	 of	 IFNa	 by	 attaching	 a	 polyethyleneglycol	molecule	 significantly	 improved	the	half-life	and	thus	the	pharmacokinetics	of	IFNa	without	any	loss	in	biological	activity	53,	54.	This	allowed	for	a	reduction	of	the	injection	frequency	from	daily	to	weekly	and	at	the	same	time	increased	the	antiviral	efficacy	of	IFNα	by	about	another	10–15%61.	It	is	assumed,	 that	 the	 sustained	 high	 serum	 concentration	 of	 pegIFNα	 provide	 for	interrupted	 antiviral	 activity	 through	 a	 permanent	 stimulation	 of	 the	 IFN	 signaling	pathways,	 whereas	 the	 serum	 concentrations	 of	 standard	 IFN-α	 (with	 an	 elimination	half-life	 of	 4	 to	10	hours)	decline	below	pharmacologically	 active	 levels	 in	 the	 second	half	of	each	48-hour	dosing	interval61	62.	However,	there	is	no	experimental	evidence	to	support	this	hypothesis.	On	the	contrary,	IFNα-induced	signalling	through	the	JAK–STAT	pathway	 becomes	 refractory	 in	 a	 matter	 of	 hours63,	 and	 in	 mice	 hepatocytes	 remain	unresponsive	 to	 further	 stimulation	 with	 high	 doses	 of	 IFNα	 for	 several	 days64,	 65.	Whatever	the	mechanisms,	pegIFNα	was	significantly	more	effective	and	in	combination	with	ribavirin	achieved	SVRs	of	56%	of	treated	patients,	an	increase	of	>	10	%	compared	to	conventional	IFNα2a.	54.	In	2002,	the	combination	of	pegIFNα	with	ribavirin	for	6	to	12	months	therefore	became	the	standard	of	care	protocol	for	the	subsequent	decade.			Direct-acting	antiviral	agents	(DAAs)	In	the	last	years,	pegIFNα	and	ribavirin	have	been	gradually	replaced	by	a	new	and	very	potent	 class	 of	 	 DAAs.	 In	 contrast	 to	 IFN	 α,	which	 induces	 the	 body's	 innate	 antiviral	immune	 response,	DAAs	are	designed	 to	directly	 inhibit	 viral	proteins	 involved	 in	 the	HCV	life	cycle.	Three	important	HCV	DAA	classes	are	highlighted:	(1)	NS3/4A	protease	inhibitors,	which	 inhibit	HCV	polyprotein	processing,	 (2)	NS5B	polymerase	 inhibitors,	which	 inhibit	 HCV	 RNA	 replication,	 and	 (3)	 NS5A	 inhibitors,	 which	 inhibit	 viral	replication	 and	 assembly,	 although	 the	 precise	mechanism	 of	 action	 is	 unknown66.	 In	2011,	 the	 first	 two	DAAs	 that	 act	 as	NS3/4A	protease	 inhibitors	 (PI)	were	developed,	boceprevir	and	telaprevir.		In	combination	with	pegIFNα	and	ribavirin	these	triple-drug	management	could	achieve	SVR	in	more	than	70%55,	67.	Treatment	with	first-generation	PIs	 had	 substantial	 tolerability	 issues	 with	 additional	 side	 effects,	 including	 severe	anemia,	 serious	 skin	 reactions	 or	 rash,	 and	 dysgeusia,	which	 added	 to	 the	 underlying	tolerability	issues	associated	with	pegIFN	and	RBV.	Development	and	implementation	of	novel	 DAAs	 progress	 fast.	 Because	 of	 the	 considerable	 toxicity	 of	 recombinant	 IFNα,	major	 efforts	 are	 underway	 to	 develop	 IFN-free	 treatments.	 In	 2013	 two	 additional	
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DAAs	were	approved	(Sofosbuvir	und	Simeprevir).	In	2014,	multiple	IFN-free	regimens	(in	 some	 cases,	 also	RBV-free)	 became	 available	 for	 the	 treatment	 of	HCV	 genotype	1	infection	(Table	1).	The	approval	of	 these	DAAs	 further	 transformed	the	 landscape	 for	the	 treatment	 of	 HCV,	 leading	 to	 both	 improved	 efficacy	 and	 tolerability.	 IFN-free	regimens	allow	shorter	treatment	duration	with	SVR	rates	reaching	more	than	90%68,	69.	Whether	such	IFN-free	regimens	will	completely	replace	recombinant	IFNs	in	all	patient	subgroups	is	unclear,	since	many	of	the	next-generation	drugs	are	still	in	the	early	phase	of	clinical	development	and	their	overall	 	efficacy	and	safety	in	larger	patient	groups	is	not	yet	known.	Specific	concerns	include	drug–drug	interactions,	efficacy	in	patients	that	are	 also	 under	 immunosuppressive	 therapy	 (after	 organ	 or	 haematopoietic	 stem	 cell	transplantation,	 or	 in	 patients	 with	 severe	 autoimmune	 diseases)	 or	 in	 patients	 with	impaired	kidney	function15.			
	Table	1.	Currently	Available	HCV	DAAs	by	Drug	Class			
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1.2.	 Interferon	signaling	1.2.1.	Interferons	and	their	receptors	Isaacs	and	Lindenmann	identified	IFN	in	1957	during	their	studies	of	the	phenomenon	of	 viral	 interference	 characterized	 as	 the	 ability	 of	 an	 active	 or	 inactivated	 virus	 to	interfere	with	the	growth	of	an	unrelated	virus70.	IFNs	are	a	family	of	cytokines	classifed	as	type	I,	II	or	III	IFNs	based	on	the	specific	cell	surface	receptors	they	recognize.	Human	type	I	IFNs	include	12	highly	similar	members	of	the	IFNα-family,	a	single	IFN-β	as	well	as	IFNs-ε,	κ,	ω	and	ν.		Type	I	IFNs	bind	to	the	IFN-α/IFN-β	receptor	(IFNAR)	that	consists	of	the	two	subunits	IFNAR1	and	IFNAR271.	IFNAR	is	ubiquitely	expressed	on	virtually	all	cells	in	the	body.	There	is	only	one	type	II	IFN,	IFN-	γ.	It	is	produced	mainly	by	NK	and	T	cells	 in	response	to	stimulation	with	antigens	or	mitogens72,	73.	 IFNγ	binds	to	a	distinct	receptor,	the	interferon	gamma	receptor	(IFNGR)	consisting	of	the	two	subunits	IFNGR1	(previously	 called	 α	 chain)74	 and	 IFNGR2	 (previously	 called	 β	 chain	 or	 accessory	factor)75,	76.	More	recently,	a	type	III	 IFNs	have	been	described.	 	The	3	members	of	 the	type	 III	 class,	 IFNλ2,	 IFNλ3	 and	 IFNλ1(also	 known	 as	 IL28A,	 IL28B	 and	 IL29	respectively),	signal	through	the	IFN-λ	receptor	consisting	of	the	IL-10R2	chain	shared	with	the	IL-10	receptor,	and	a	unique	IFNλ	chain77,	78.	Type	I	IFNs	and	type	III	IFNs	are	produced	by	cells	 infected	with	viruses	and	by	key	sentinel	cells	of	the	innate	immune	system	such	as	macrophages	and	dendritic	 cells	 (DCs).	 Importantly,	macrophages	and	DCs	 do	 not	 have	 to	 be	 infected	 by	 viruses	 in	 order	 to	 produce	 IFNs.	 Instead,	 they	constantly	sample	the	extracellular	millieu	for	the	presence	of	foreign	materials	such	as	virus	containing	remnants	of	apoptotic	cells	and	intact	viral	particles79.	It		has		also		been		postulated		that		type	III	IFNs		might		be		induced		by	stimulation	of	cells	with	type	I	or	III	IFN,	suggesting	that	 this	class	of	cytokines	belongs	at	 the	same	time	to	the	group	IFN-stimulated	genes80.		1.2.2.	Induction	of	interferons	Cells	produce	IFNα,	IFNβ	and	IFNλ	in	response	to	infection	by	a	variety	of	viruses.	Two	important	 pathways	 that	 detect	 components	 of	 viral	 genomes	 and	 trigger	 type	 I	 and	type	 III	 IFN	expression	have	been	discovered	and	characterised	 in	recent	years.	These	include	 the	 toll-like	receptor	 (TLR)	dependent	pathway81,	82	and	 the	cytosolic	pathway	triggered	 by	 binding	 of	 viral	 RNA	 to	 the	 RNA	 helicases	 retinoic	 acid	 inducible	 gene-I	(RIG-I)	 and	melanoma	differentiation	antigen	5	 (MDA5)83.	Both	pathways	 converge	 to	
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1.3.	Innate	and	adoptive	immune	response	in	Hepatitis	C	infection		1.3.1.	Innate	and	adaptive	immune	response	in	acute	HCV	(AHC)	infection	The	 acute	 phase	 of	 HCV	 infection	 is	 divided	 in	 an	 early	 acute	 phase	 prior	 to	 the	activation	 and	 recruitment	 of	HCV	 specific	 T	 cells	 in	 the	 liver,	 and	 a	 late	 acute	 phase,	characterized	by	 the	 adaptive	 immune	 response	 (Figure	8).	 Innate	 immune	 responses	are	 the	 first	 line	 of	 defense	 against	 pathogens	 including	 viral	 infections.	 IFNs	 are	 the	central	 cytokine	 mediators	 responsible	 for	 the	 induction	 of	 a	 innate	 antiviral	 state	within	cells	and	also	for	the	activation	and	regulation	of	the	cellular	components	of	the	innate	immune	system	such	as	natural	killer	(NK)	cells98.	However,	little	is	known	about	the	 early	 induction	 of	 innate	 immune	 responses	 in	 HCV	 infection	 because	 the	 acute	phase	 of	 HCV	 infection	 is	 only	 infrequently	 diagnosed	 due	 to	 the	 very	 mild	 and	unspecific	clinical	manifestation.	Furthermore,	the	few	prospective	studies	of	acute	HCV	infection	 that	were	done	with	health-care	workers	 after	 accidental	needle	 stick	 injury	typically	focused	on	the	analysis	of	the	adaptive	immune	response	to	HCV	infection.	Our	current	 understanding	 of	 the	 early	 hepatic	 events	 during	 HCV	 infection	 derives	 from	studies	 using	 serial	 liver	 biopsy	 and	 blood	 samples	 obtained	 from	 experimentally	infected	 chimpanzees99,	 100,	 101,	 102.	 High	 HCV	 viral	 titers	 have	 been	 observed	 in	chimpanzee	 serum	 and	 liver	 already	within	 days	 after	 inoculation.	 After	 a	 very	 rapid	increase	in	the	first	2	weeks	after	an	infection,	HCV	viral	loads	remain	stable	for	several	weeks,	until	 the	emergence	of	a	cellular	 immune	response	 in	 the	 liver.	Transcriptomic	analysis	of	the	liver	biopsy	derived	RNA	revealed	induction	of	type	I	IFN	response	in	the	early	 acute	 phase	 of	 infection.	 The	 extent	 and	 duration	 of	 the	 ISG	 induction	 was	positively	 correlated	 with	 the	 viral	 load.	 However,	 despite	 this	 apparent	 and	 strong	innate	 immune	 response	 during	 the	 acute	 phase	 of	HCV	 infection,	 the	 infection	 is	 not	cleared	in	most	cases.	Although	there	is	evidence	that	HCV	could	trigger	IFN	production	in	the	cells	it	infects,	this	has	so	far	not	been	proven	and	the	cellular	source	and	type	of	IFN	that	triggers	the	massive	ISG	induction	during	acute	HCV	infection	still	remains	to	be	identified.	 	While	several	reports	suggest	that	HCV	triggers	type	III	IFN	induction	in	primary	 human	 PHH	 it	 infects42,	 103,	 104,	 other	 groups	 reported	 that	 plasmacytoid	dendritic	 cells,	 stimulated	 by	 cell-cell	 contact	with	 infected	 hepatocytes,	might	 be	 the	source	of	primarily	type	I	IFNs105.	More	recent	studies	detected	up-regulation	of	mRNA	of	type	III	(but	not	type	I)	IFNs	in	liver	biopsies	of	chimpanzees	and	an	increase	of	type	III	IFN	protein,	primarily	IFN-λ1	(IL29),	in	the	serum	of	chimpanzees.	
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In	contrast	to	the	innate	immune	responses	that	are	induced	within	days	after	infection,	adaptive	immune	responses,	that	correspond	to	the	late	acute	phase	become	detectable,	for	 reasons	not	 yet	 clearly	understood,	 only	 after	6–8	weeks101,	106,	107	 (Figure	8).	This	phase	 lasts	 4–10	weeks	 and	 is	 clinically	 characterized	 by	 elevated	 transaminases	 and	sometimes	 icterus,	 and	 leads	 to	 clearance	 of	 the	 infection	 in	 about	 30%	 of	 infected	individuals.	 There	 is	 general	 consensus	 from	 a	 number	 of	 immunological	 studies	 that	HCV	 elimination	 requires	 sustained,	 strong	 and	 multispecific	 HCV-specific	 CD4+	 and	CD8+	T	cell	responses79.	The	combination	of	non-cytolytic	inhibition	of	virus	replication	and	 production	 reduces	 viral	 spread	 while	 the	 adaptive	 response	 eliminates	 the	 still	infected	cells108.		
   		
Figure	8:	Natural	course	of	HCV	Infection				1.3.2.	Innate	immune	response	during	chronic	HCV	infection		The	 chronic	 phase	 of	 HCV	 infection	 is	 primarily	 characterized	 by	 a	 largely	 ineffective	cellular	 immune	 response	probably	 caused	by	 a	 combination	of	T	 cell	 exhaustion	 and	emergence	of	viral	escape	mutants.	Even	though	the	IFN	system	is	still	activated	in	the	liver,	it	is	not	is	not	sufficient	to	clear	the	virus	(reviewed	in79).	In	humans	who	develop	chronic	infection,	ISG	induction	varies	considerably	between	individuals.	In	about	half	of	Caucasian	patients,	hundreds	of	type	I	or	III	ISGs	are	constantly	expressed	at	high	levels	in	 the	 liver,	whereas	 the	other	half	 has	no	detectable	 induction	of	 the	 innate	 immune	
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system109.	Apart	from	a	strong	association	of	allelic	variants	near	the	IFN-λ4	gene	with	ISG	induction,	little	is	known	about	the	factors	that	determine	the	activation	level	of	the	IFN	system.110,	111,	112.		HCV	persists	for	decades	despite	the	expression	of	hundreds	of	ISGs93.	Furthermore,	in	contrast	to	what	is	seen	during	AHC,	there	is	no	significant	correlation	between	serum	or	 intrahepatic	 viral	 loads	 with	 ISG	 expression	 levels109.	 The	 interplay	 between	 viral	replication	 levels	 and	 ISG	 induction	 in	 the	 liver	 is	 still	 unknown,	 Nevertheless,	intrahepatic	 ISG	 expression	 seems	 to	 be	 maximal	 in,	 but	 not	 restricted	 to	 the	 HCV	infected	cell	as	determined	by	simultaneous	HCV	RNA	and	ISG	mRNA	by	fluorescent	in	situ	hybridization	 suggesting	 that	HCV	 itself	 is	 the	main	driver	of	 the	observed	 innate	response109.			1.3.3.	 Non-response	 to	 PegIFN-α	 in	 CHC	 patients	 with	 an	 activated	endogenous	IFN	system	in	the	liver	It	is	known	that	patients	with	an	activated	endogenous	IFN	system	are	poor	responders	to	IFN-α	based	therapies93,	113,	114.	Analysis	of	paired	liver	biopsies	obtained	before	and	4	h	 after	 the	 first	 injection	 of	 PegIFN-α2	 revealed	 that	 patients	 with	 an	 activated	endogenous	 IFN	 system	had	hundreds	of	 ISGs	 expressed	at	high	 levels	 already	before	treatment.	 Staining	of	 these	biopsies	 for	 the	phosphorylated	 form	of	 STAT1	 showed	a	faint	staining	in	nuclei	of	hepatocytes	in	pre-treatment	biopsies,	and	no	further	increase	of	phospho-STAT1	signals	4	h	after	PegIFN-α	injections.	In	contrast,	no	phospho-STAT1	signals	 were	 detected	 in	 pre-treatment	 biopsies	 of	 patients	 without	 activated	endogenous	IFN	system,	but	PegIFN-α	injections	 induced	a	very	prominent	and	strong	activation	 and	nuclear	 translocation	within	4	h93.	 The	 reason	 for	 the	 refractoriness	 of	IFN-α	induced	Jak-STAT	signaling	is	not	entirely	clear,	but	there	is	evidence	that	USP18	is	 an	 important	 factor115.	 USP18	 was	 strongly	 expressed	 in	 a	 large	 number	 of	hepatocytes	 in	 liver	 biopsies	 from	patients	with	 CHC	 and	 a	 pre-activated	 endogenous	IFN	system	115.						
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HCV genotype 4 4 1 1 1 1 4 3 3 3 3 1 2 2 1 3 2 3 1 1 4 1
inflammation 2 3 1 2 3 2 2 1 2 2 3 3 2 3 3 1 2 1 1 1 1 1
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● ● ●FDR < 0.1 (low ISG vs. high ISG) FDR >= 0.1 (low ISG vs. high ISG) not tested
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PCA, all protein−coding genesa
























































































































b miRNA targets (HITS−CLIP, Luna 2015)
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● ● ●FDR < 0.1 pegIFNa FDR >= 0.1 pegIFNa not tested
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Biopsy No Patient No Age Sex Patient classification HCV GT Viral load, log IU/mL METAVIR Comment
A584 1 37 m CHC	low	ISG 3 4.9 A1/F2
A764 3 38 m CHC	low	ISG 4 4.08 A2/F2
A720 4 51 f CHC	low	ISG 1 6.82 A1/F2
C552 5 49 f CHC	low	ISG 4 5.68 A2/F2
A748 8 30 m CHC	low	ISG 3 7.07 A2/F2
A727 9 57 f CHC	low	ISG 1 5.95 A2/F2
B215 16 34 m CHC	low	ISG 3 5.56 A2/F2
A991 6 42 f CHC	high	ISG 3 5.49 A1/F2
B199 7 41 m CHC	high	ISG 3 5.66 A1/F2
B320 17 57 f CHC	high	ISG 2 5.18 A2/F2
B929 19 38 f CHC	high	ISG 1 5.05 A1/F1 no	therapy
C71 20 41 f CHC	high	ISG 1 7.14 A1/F1 no	therapy
C106 21 51 m CHC	high	ISG 4 5.97 A1/F2 no	therapy
C186 22 47 f CHC	high	ISG 1 6.01 A1/F1 SVR	24	after	triple	therapy	with	pegIFN,	Ribavirin	and	boceprevir
B986 23 49 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
paired	tumor	and	non-tumor	biopsy,	metastase	of	brest	cancer,	
normal	histology	of	non-tumor	biopsy
C145 25 43 f control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
C173 26 62 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
paired	tumor	and	non-tumor	biopsy,	metastase	of	lung	cancer,	
normal	histology	of	non-tumor	biopsy
C369 28 37 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
C250a 27 80 m control	(non-CHC)
C51a 24 63 f control	(non-CHC)
Baseline 4-week 12-week 4-week 12-week Follow-up
A	584 A	584-2 1 2 37 m 3 4.9 neg neg RVR cEVR SVR A1/F2 4h pegIFN-α2b
A	609 A	609-2 2 3 54 f 2 4.95 neg neg RVR cEVR SVR A3/F3 4h pegIFN-α2b
A	764 A	764-2 3 5 38 m 4 4.08 1.66 neg non-RVR cEVR SVR A2/F2 4h pegIFN-α2b
A	720 A	720-2 4 6 51 f 1 6.82 3.52 neg non-RVR cEVR SVR A1/F2 4h pegIFN-α2b
C552 C591 5 - 49 f 4 5.68 2.75 neg non-RVR cEVR ongoing A2/F2 16h pegIFN-α2b
A	991 A991-2 6 8 42 f 3 5.49 neg neg RVR cEVR SVR A1/F2 16h pegIFN-α2b
B	199 B	217 7 9 41 m 3 5.66 neg neg RVR cEVR SVR A1/F2 16h pegIFN-α2b
A	748 A	748-2 8 10 30 m 3 7.07 neg neg RVR cEVR SVR A2/F2 48h pegIFN-α2b
A	727 A	727-2 9 11 57 f 1 5.95 neg neg RVR cEVR SVR A2/F2 48h pegIFN-α2b
B	254 B	284 10 12 37 m 3 6.72 1.28 neg non-RVR cEVR SVR A3/F2 48h pegIFN-α2b
A	616 A	616-2 11 13 62 m 4 7.16 neg neg RVR cEVR SVR A3/F4 96h pegIFN-α2b
B	136 B	178 12 14 43 m 1 5.6 1.63 neg non-RVR cEVR SVR A3/F2 96h pegIFN-α2b
B	283 B	304 13 15 40 m 1 5.16 1.41 neg non-RVR cEVR SVR A3/F4 96h pegIFN-α2b
A	707 A	707-2 14 16 25 f 1 2.64 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
A	972 A	972-2 15 17 70 m 2 6.86 1.84 neg non-RVR cEVR SVR A2/F3 144h pegIFN-α2b
B	215 B	247 16 18 34 m 3 5.56 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
B	320 B	371 17 19 57 f 2 5.18 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
B	346 B	401 18 20 57 m 1 6.54 4.59 3.33 non-RVR EVR Interrupted A3/F4 144h pegIFN-α2b
HCV GTBiopsy No Patient No Patient No (Dill et al., JC, 2014I) Age Sex
Viral load, log IU/mL Response









































4. Conclusion		 In	 the	 liver,	 cell-intrinsic	 adaptive	 changes	 to	HCV	 infections	 are	difficult	 to	detect	because	of	the	gene	expression	changes	induced	by	the	innate	immune	response,	mainly	through	IFNs,	can	mask	the	more	subtle	cell-intrinsic	changes	induced	be	HCV	directly	in	infected	cells.	Due	to	a	genetic	polymorphism	in	the	IFNl4	gene,	ISG	induction	in	humans	is	 highly	 variable110,	 116.	 To	 specifically	 identify	 dysregulated	 genes	 other	 than	 IFN	stimulated	genes,	we	selected	a	set	of	liver	biopsies	from	patients	without	endogenous	ISG	 induction	 and	 compared	 gene	 expression	 in	 these	 “ISG	 low”	 samples	 with	 global	gene	 expression	 in	 a	 set	 of	 control	 samples	 from	non-infected	patients	with	 a	 normal	liver.	 We	 found	 that	 gene	 expression	 changes	 between	 uninfected	 liver	 samples	 and	biopsies	without	detectable	 ISG	expression	mainly	reflect	 the	presence	of	 immune	cell	infiltrates	 in	 the	 latter	 group.	 Contrary	 to	 our	 expectations,	 we	 could	 not	 detect	expression	 changes	 of	 genes	 involved	 in	 cellular	 responses	 to	 HCV	 described	 in	 cell	culture.	 For	 example,	 a	previous	 large-scale	 analysis	 of	differential	 gene	 expression	 in	HCV-infected	Huh-7.5	cells	revealed	that	860	genes	showed	a	2-fold	or	higher	change	in	expression.	 Gene	 ontology	 analysis	 revealed	 that	 many	 of	 them	 are	 involved	 in	 DNA	damage/oxidative	 stress	 response,	 cytochrome	 c	 release,	 cell	 death,	 cell	 cycle	 and	cytokine/growth	factor	signalling	122.		Unlike	this	in	vitro	analysis,	our	in	vivo	differential	expression	analyses	did	not	reveal	enrichments	for	these	functional	categories	of	genes.	Using	 a	 targeted	 approach	 by	 specifically	 analysing	 genes	 previously	 reported	 to	 be	changed	 in	 HCV-infected	 Huh-7.5	 cells	 122,	 we	 could	 indeed	 identify	 a	 core	 set	 of	 25	genes	that	are	differentially	expressed	following	HCV	infection	in	both	Huh	7.5	cells	and	in	 liver	 samples	 from	 patients	 without	 IFN	 system	 activation.	 This	 common	 gene	 set	included	several	cell	cycle	associated	genes,	such	as	UBD,	ITIH1	and	BIRC3.	25	out	of	860	genes	seems	to	be	a	very	low	number,	but	statistical	analysis	of	the	data	revealed	that	this	 is	 significantly	more	 than	expected	by	 chance	alone.	We	conclude	 that	our	 in	vivo	analysis	 confirms	 the	 induction	 of	 a	 small	 but	 significant	 number	 of	 genes	 that	 have	been	described	to	be	induced	by	HCV	in	cell	culture	experiments.	The	huge	differences	between	 in	vivo	 and	 in	vitro	could	 be	 due	 to	 the	 very	 high	 viral	 concentration	 in	 cell	culture:	 the	number	of	HCV	virions	per	 infected	cell	 is	between	1	and	8	 in	 the	human	liver,	but	can	be	as	high	as	500	to	1000	in	the	Huh-7.5	cell	culture	model.	Moreover	only	1-55%	of	the	hepatocytes	in	the	human	liver	are	HCV	positive109.	Therefore,	changes	in	
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infected	 hepatocytes	 could	 be	masked	 by	 unchanged	 gene	 expression	 in	 non-infected	hepatocytes	and	non-parenchymal	liver	cells.		 The	 second	aim	of	 the	work	was	 to	 characterize	 IFN	 stimulated	 changes	 in	 the	liver	 trancriptome	 of	 patients	 with	 chronic	 hepatitis	 C	 (CHC)	 and	 an	 activated	endogenous	IFN	system.	To	do	this,	we	contrasted	gene	expression	levels	between	non-CHC	 control	 samples	 and	 CHC	 samples	 with	 high	 ISG	 expression	 (“ISG	 high”).	 We	observed	503	protein-coding	genes,	80	candidate	long	non-coding	RNAs	and	125	other	genes	differentially	 expressed	genes	 in	 the	 latter	group.	 	As	expected,	 the	most	highly	up-regulated	protein-coding	genes	were	known	ISGs.	The	up-regulated	long	non-coding	RNAs	 included	 a	 previously	 described	 interferon-inducible	 transcript,	 NRIR	 123.	However,	most	of	the	lnc	RNAs	have	not	been	described	previously	in	the	context	of	HCV	infections,	and	their	function,	if	any,	remains	to	be	explored.		 The	third	aim	of	the	work	addressed	a	longstanding	conundrum	in	the	field:		Despite	a	strong	induction	of	hundreds	of	ISGs	the	endogenous	IFN	system	is	ineffective	against	HCV,	whereas	therapies	with	pegIFNα	were	curative	in	many	patients.	Two	alternative	explanations	were	explored:	Either	some	critical	ISGs	are	exclusively	induced	by	pegIFNα,	or	pegIFNα	induces	the	same	ISGs	but	at	a	higher	level	than	the	endogenous	IFNs.	Our	data	clearly	indicate	that	the	second	explanation	is	more	likely.	The	same	set	of	ISGs	was	induced	by	pegIFNa	and	the	endogenous	IFN	system,	but	with	lower	induction	levels	in	the	latter.			 The	forth	aim	of	the	study	was	to	characterize	the	expression	dynamics	of	non-coding	 genes,	 including	 long	 non-coding	 RNAs	 and	miRNA	 transcripts	 in	 response	 to	HCV	 infections	 and	 to	pegIFNα	 treatments.	Our	 analysis	 revealed	 that	 numerous	non-coding	transcripts	are	down-regulated,	in	particular	at	the	16h	time	point.	These	down-regulated	 genes	 include	11	miRNA	 “host”	 genes.	Most	 interesting	 of	 them	 is	miR-122,	because	 it	 is	 an	 essential	 host	 factor	 for	 HCV	 replication29.	 Detailed	 functional	experiments	 in	Huh7	cells	brought	evidence	that	HCV	 infection	 leads	to	significant	de-repression	of	miR-122	target	genes	due	to	this	sponging	effect1.	At	first	sight,	our	in	vivo	transcriptomic	analysis	appeared	to	confirm	this	observation,	as	miR-122	target	genes	had	higher	expression	levels	in	HCV-infected	compared	to	control	biopsies.	However,	a	closer	 look	 revealed	 the	 same	pattern	 for	 other	miRNAs	 highly	 expressed	 in	 the	 liver	
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